Arranta Bio Acquires Captozyme
November 13, 2019
Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.
- Buyers
- Arranta Bio
- Targets
- Captozyme
- Platforms
- Arranta Bio
- Industry
- Biotechnology
- Location
- Florida, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.